Hannokinol is primarily investigated for its potential antiparasitic properties, particularly against protozoan parasites such as Plasmodium species, which cause malaria. It has shown promising in vitro activity by inhibiting parasite growth through interference with mitochondrial function and redox balance. Its mechanism may involve the disruption of electron transport chains in parasite cells, leading to oxidative stress and cell death. Due to its natural origin and structural profile, hannokinol serves as a lead compound in the development of new antimalarial agents, especially in the face of increasing drug resistance. Research also explores its anti-inflammatory and immunomodulatory effects, which could support its use in treating infection-related inflammation. However, its application remains largely experimental, with ongoing studies focused on improving stability, bioavailability, and selectivity.